Alliance Wealth Management Group Immuno Gen, Inc. Transaction History

Alliance Wealth Management Group

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 21, 2018	SELL	$6.7 - $12.95 $67,000 - $129,500	-10,000 Closed	0 $0
Q4 2017 Jan 31, 2018	SELL	$5.07 - $7.92 $50,700 - $79,200	-10,000 Reduced 50.0%	10,000 $64,000
Q3 2017 Nov 09, 2017	BUY	$5.4 - $8.47 $108,000 - $169,400	20,000	20,000 $154,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Alliance Wealth Management Group, based on Form 13F filings with the SEC.

Stay updated on Alliance Wealth Management Group with notifications on news.